Skip to content

There are two major types of the human immunodeficiency virus. HIV-1, which was discovered first, is the most widespread type worldwide. HIV-2 is more than 55% genetically different from HIV-1.

HIV-2 is most common in western Africa and is becoming more common in India, although numbers there are still relatively small. Small numbers of cases have also been seen in Portugal, France, other European countries including the UK and the Americas, largely in individuals of west African origin or their sexual partners.

Each major type of virus can be further broken down into groups, which themselves can be subdivided into clades or subtypes. HIV-1 comprises groups M (main), O (outlier), and N (non-M or O). There are two main HIV-2 subtypes, A and B.

Due to the genetic difference, HIV-1 and HIV-2 antigens are distinct enough that if a diagnostic test is developed only to detect HIV-1, it will not reliably detect HIV-2. However, tests which are sensitive to both types of virus are available. It is important to use a test that is sensitive to HIV-2, especially when testing someone who has lived in a country where HIV-2 is common or has had a sexual partner from one of those countries. Moreover, if a person has clinical signs of HIV infection (e.g. recurrent opportunistic infections) but does not test positive to a test which is sensitive only to HIV-1, then testing specifically for HIV-2 would be appropriate.

Anti-HIV medications from the non nucleoside reverse transcriptase inhibitor (NNRTI) class are not active against HIV-2. This includes efavirenz, rilpivirine, doravirine, etravirine and nevirapine. Regimens based on an integrase inhibitor, or a protease inhibitor, are recommended.

Roger Pebody

Roger Pebody

Commissioning Editor

Roger joined aidsmap in 2008 and was Managing Editor from 2018 to 2024. As a freelancer, he now edits aidsmap’s news and conference coverage, as well as working on updates to About HIV pages. He is also a contributing science editor for TheBodyPro, a freelance journalist for The Lancet HIV, and a medical writer helping researchers prepare articles for peer-reviewed journals. He began working on HIV at Gay Men Fighting AIDS in the mid-1990s.

Basic information

Myths and facts

Myths and facts

What is an elite controller?

What is a vaccine?

Gustavo Fring/Pexels

What’s the latest news on HIV vaccines?

CDC/Unsplash

Why is it so difficult to make an HIV prevention vaccine?

Marco Verch. Creative Commons licence.

Why have we got COVID vaccines but not HIV vaccines?

CDC/Unsplash

Could an mRNA vaccine protect against HIV?

Mufid Majnun/Unsplash

The search for an HIV prevention vaccine

Image: Adam Gregor/Shutterstock.com

Why is HIV hard to cure?

Liya Graphics/Shutterstock.com

The search for an HIV cure

Kateryna Kon/Shutterstock.com

Cases of HIV cure

Image from Timothy Ray Brown's interview with German magazine Stern in 2010.

HIV cure

HIV cure

Ethics in cure research

Mareike Günsche | www.aspect-us.com

Diversity and equity in HIV cure research

Mareike Günsche | www.aspect-us.com

Should HIV controllers take HIV treatment?

A doctor and patient talking in a doctor's office.

Clinical trials

Chinnapong/Shutterstock.com

Thinking about joining a clinical trial?

Mareike Günsche | www.aspect-us.com

Phases of clinical trials

A doctor wearing a light brown shirt and a stethoscope around his neck sitting at a desk and talking to a patient who's wearing a purple t-shirt.

HIV-1 subtypes

Image: Kateryna Kon/Shutterstock.com